Cursiefen C, Maruyama K, Bock F, Saban D, Sadrai Z, Lawler J, Dana R, Masli S (2011)
Publication Type: Journal article
Publication year: 2011
Book Volume: 208
Pages Range: 1083-92
Journal Issue: 5
DOI: 10.1084/jem.20092277
Lymphangiogenesis plays an important role in tumor metastasis and transplant outcome. Here, we show that thrombospondin-1 (TSP-1), a multifunctional extracellular matrix protein and naturally occurring inhibitor of angiogenesis inhibits lymphangiogenesis in mice. Compared with wild-type mice, 6-mo-old TSP-1-deficient mice develop increased spontaneous corneal lymphangiogenesis. Similarly, in a model of inflammation-induced corneal neovascularization, young TSP-1-deficient mice develop exacerbated lymphangiogenesis, which can be reversed by topical application of recombinant human TSP-1. Such increased corneal lymphangiogenesis is also detected in mice lacking CD36, a receptor for TSP-1. In these mice, repopulation of corneal macrophages with predominantly WT mice via bone marrow reconstitution ameliorates their prolymphangiogenic phenotype. In vitro, exposure of WT macrophages to TSP-1 suppresses expression of lymphangiogenic factors vascular endothelial growth factor (VEGF)-C and VEGF-D, but not of a primarily hemangiogenic factor VEGF-A. Inhibition of VEGF-C is not detected in the absence or blockade of CD36. These findings suggest that TSP-1, by ligating CD36 on monocytic cells, acts as an endogenous inhibitor of lymphangiogenesis.
APA:
Cursiefen, C., Maruyama, K., Bock, F., Saban, D., Sadrai, Z., Lawler, J.,... Masli, S. (2011). Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. Journal of Experimental Medicine, 208(5), 1083-92. https://doi.org/10.1084/jem.20092277
MLA:
Cursiefen, Claus, et al. "Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes." Journal of Experimental Medicine 208.5 (2011): 1083-92.
BibTeX: Download